© 2020 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
All News
Immunotherapy-Based Combos May be Necessary in Neuroendocrine Neoplasms
May 22, 2020
The immune checkpoint inhibitor induced 1 objective response but appeared safe as treatment of patients with metastatic high-grade neuroendocrine neoplasms in 2 open-label phase 2 clinical trials.
Trending News on Targeted Oncology, Week of May 22, 2020
May 22, 2020
Targeted Oncology reviews trending news online for the week of May 22, 2020, including recent news from the FDA, updates in oncology, and new information regarding COVID-19.
FDA Approves Brigatinib as Frontline Treatment of ALK-Positive Metastatic NSCLC
May 22, 2020
The FDA has granted approval to brigatinib for the frontline treatment of patients with ALK-positive metastatic non–small cell lung cancer, as detected by an FDA-approved test.
Trastuzumab Deruxtecan Receives Orphan Drug Designation from FDA for Gastric Cancer
May 22, 2020
Fam-trastuzumab deruxtecan-nxki has received an Orphan Drug designation for the treatment of patients with gastric or gastroesophageal junction cancer.
Neoadjuvant Durvalumab Regimen Improves Responses in Triple-Negative Breast Cancer
May 21, 2020
In an interview with Targeted Oncology, Lajos Pusztai, MD, DPhil, discussed the findings from the phase I/II clinical trial of durvalumab in combination with concurrent nab-paclitaxel and doxorubicin plus cyclophosphamide in the neoadjuvant setting for patients with triple-negative breast cancer.
Durvalumab/Chemotherapy Combination Improves Survival in Mesothelioma
May 21, 2020
"Durvalumab plus standard chemotherapy delivered a promising median overall survival rate for patients with previously untreated, inoperable malignant pleural mesothelioma."
Tweet Chat Recap: Sequencing Strategies for a Post-Docetaxel Patient with Metastatic Castration-Resistant Prostate Cancer
May 21, 2020
In an interview with Targeted Oncology, following a tweet chat on prostate cancer, Tian Zhang, MD, discussed the key takeaways from the tweet chat discussion and highlighted both the role of molecular testing and the impact of the recent FDA approvals in prostate cancer.
Personalized Treatment Approaches Improve Outcomes for Patients With Ovarian Cancer
May 20, 2020
In an interview with Targeted Oncology, Robert L. Coleman, MD, FACOG, FACS, discussed the importance of molecular testing in ovarian cancer and how the treatment landscape will continue to evolve in tailoring treatment to patients based on the biology of their tumors, which was the topic of his lecture at the 2020 Society for Gynecologic Oncology (SGO) Annual Meeting.
FDA Approves CDx Tests for Olaparib in HRR-Mutant mCRPC
May 20, 2020
Two companion diagnostic assays were granted FDA approval to identify male patients with metastatic castration-resistant prostate cancer who are eligible for treatment with olaparib.
Ruxolitinib Plus Post-Transplant Cyclophosphamide Controls GVHD in Myelofibrosis
May 20, 2020
“In this study, we evaluated ruxolitinib as a bridge, relapse, and GVHD prevention agent in patients with myelofibrosis. The regimen was well tolerated, with an acceptable rate of organ toxicity."